CPT1A and neoplasm: Finally, we designed iRGD‐engineered exosomes to transport CPT1A siRNA specifically to colon cancer cells and tumours, which might efficiently silence CPT1A and serve as a potential carrier to reverse oxaliplatin resistance in drug‐resistant colon cancer.